Developer docs
API playgroundTry for free, no card

Search company profiles

InspiroGene

Full company profile

uuid0099dlk

Namestring
InspiroGene
Legal namestring
InspiroGene (Trademark of McKesson Corporation)
Websiteurl
inspirogene.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

InspiroGene is a wholly-owned business unit of McKesson Corporation (NYSE: MCK) that provides end-to-end commercialization services for cell and gene therapy (CGT) manufacturers. The platform integrates five service lines: Third-Party Logistics (3PL) with 12,000 sq ft of dedicated cryo/ultra-frozen storage within a 1 million sq ft Louisville, KY distribution center; Specialty Distribution with extensive treatment center coverage; Specialty Pharmacy with 50-state licensure and two redundant dispensing sites; the InspiroCare Patient Hub offering clinical case management, reimbursement support, and 24/7 care team access; and InspiroLink, a purpose-built ordering platform with API-level integrations across the CGT technology ecosystem. A distinguishing capability, Biologics-in-a-Box, co-locates specialty pharmacy dispensing within the 3PL environment to minimize manufacturer-to-treatment-center transit time. The unit covers 95% of active CGT sites of care and is staffed by teams with an average of 10+ years of CGT commercialization experience.

The company operates as a B2B enterprise service provider, targeting biopharma companies commercializing cell and gene therapies through a dedicated field sales motion and configurable engagement models (high-touch, configurable, or purpose-built). Revenue is generated through managed services fees, distribution and transaction fees, pharmacy dispensing fees, and biopharma-sponsored hub service agreements. Pricing is not publicly disclosed and is tailored per manufacturer. InspiroGene's named enterprise customers include Kite Pharma (CAR T-cell distribution), Vertex Pharmaceuticals (CASGEVY gene therapy distribution), Iovance Biotherapeutics (Amtagvi specialty pharmacy, the first FDA-approved cell therapy for solid tumors), Nanoscope Therapeutics (retinal gene therapy distribution), and Precigen (specialty pharmacy and patient hub for immunotherapy launch).

Strategically, InspiroGene leverages McKesson's Fortune 10 infrastructure, 300+ manufacturer relationships, $300B+ in annual WAC sales across full-line wholesale and specialty distribution, and a 450+ person multi-site logistics operation. The unit was launched in 2024 and has rapidly accumulated enterprise partnerships through 2026, supported by thought leadership content (annual CGT Report), industry event participation, and a marketing motion centered on positioning as an 'ally' to biopharma companies navigating CGT commercialization complexity. The platform's strategic intent is to capture share of the rapidly expanding CGT pipeline (235+ therapies analyzed in 2025) by offering integrated, CGT-specialized commercialization infrastructure that bridges the gap between therapy innovation and patient access.

Short descriptiontext

InspiroGene is McKesson's dedicated cell and gene therapy commercialization business unit, providing integrated 3PL, specialty distribution, specialty pharmacy, patient hub services, and the InspiroLink ordering platform to biopharma manufacturers across 95% of US CGT sites of care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersIrving, United States
HQ citystring
Irving
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy logistics, gene therapy distribution, specialty pharmacy services, patient hub services, biologics distribution
Industry1 code
PRIMARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code1 code
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code1 code
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Cell and Gene Therapy Commercialization Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Third-Party Logistics (3PL) Services
TypeManaged Services
Description

Comprehensive 3PL services for CGT manufacturers including warehousing, distribution, transportation, customer service, and full order-to-cash services. Supports title and non-title distribution models with over $3B in annual revenue. Revenue generated through service fees for logistics, storage, kitting, and relabeling solutions.

inspirogene.com
2Specialty Distribution Services
TypeTransaction Fee
Description

Specialty distribution services with extensive treatment center coverage and optimized cash cycle management for CGT therapies. Revenue generated through distribution fees, logistics services, and financial management services.

inspirogene.com
3Specialty Pharmacy Services
TypeManaged Services
Description

End-to-end specialty pharmacy support for manufacturers, HCPs, payers, QTCs, and patients. Includes dispensing, reimbursement support, and patient management services. Revenue generated through pharmacy dispensing fees and service agreements.

inspirogene.com
4InspiroCare Patient Hub Services
TypeProfessional Services
Description

Purpose-built patient HUB services providing clinical case management, reimbursement, education, and financial assistance coordination. Revenue generated through biopharma-sponsored hub service agreements.

inspirogene.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1InspiroCare
Description

Patient HUB services for cell and gene therapy, providing personalized case management, financial assistance coordination, travel and logistics support, and educational resources for patients and caregivers.

inspirogene.com
+1 more record
Core offering1 text field

InspiroGene provides integrated commercialization services for cell and gene therapy (CGT) manufacturers, spanning third-party logistics (3PL) with cryo/cold-chain storage, specialty distribution, specialty pharmacy dispensing, and patient hub services (InspiroCare), all unified by the InspiroLink ordering platform. The offering is purpose-built for CGT commercialization, covering 95% of active US CGT sites of care and supporting biopharma manufacturers with end-to-end order-to-cash, reimbursement, and patient access workflows.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 95% of active CGT sites of care covered
+6 more records
Product overview1 text field

InspiroGene by McKesson is a cell and gene therapy (CGT) commercialization platform offering an integrated suite of services. The core portfolio consists of five interconnected service lines: Third-Party Logistics (3PL) for storage, warehousing, and distribution; Specialty Distribution for treatment center coverage and logistics; Specialty Pharmacy for dispensing and patient management; InspiroCare Patient Hub for patient support and coordination; and InspiroLink as the central ordering and tracking platform. The platform is purpose-built for CGT with specialized features including cryo/ultra-frozen storage solutions, Biologics-in-a-Box for streamlined product transit, and a Drive-By pharmacy model. Supported by McKesson's established infrastructure and 10+ years of CGT expertise, the solution covers 95% of active CGT sites of care across the US.

Product and service6 records
1Third-Party Logistics (3PL)
CategoryThird-Party Logistics
Description

Comprehensive third-party logistics services tailored for cell and gene therapy manufacturers, including cryo/ultra-frozen storage solutions, ordering systems, cash management, logistics, and data analytics; licensed across all 50 states and territories.

2Specialty Distribution
CategorySpecialty Distribution
Description

Specialty distribution network with extensive treatment center coverage and optimized cash cycle management for cell and gene therapies, offering high-touch logistics and advanced data analytics.

3Specialty Pharmacy
CategorySpecialty Pharmacy
Description

Purpose-built specialty pharmacy services dedicated to CGT for seamless site readiness, streamlined patient access and reimbursement processes, and high-touch dispensing with ongoing patient management; 50-state licensure with 2 redundant dispensing sites.

4InspiroCare Patient Hub
CategoryPatient Hub Services
Description

Purpose-built patient hub services providing personalized, compassionate support to help patients, caregivers, and providers navigate the CGT journey, including clinical case management, reimbursement support, patient education, financial assistance coordination, and 24/7 access to the care team.

5InspiroLink Ordering Platform
CategoryOrder Management Platform
Description

A purpose-built ordering application for healthcare providers ordering cell, gene, and advanced therapy treatments, supporting customized order workflows, scheduling, real-time product tracking, and API integrations across the Cell and Gene technology ecosystem.

6Treatment Center Experience
CategoryTreatment Center Services
Description

Purpose-built support for CGT commercialization at treatment centers, including site readiness, efficient site activation, and reliable patient access, leveraging McKesson's national network of treatment centers.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-01
Description

InspiroGene by McKesson expanded U.S. patient access to Kite's CAR T-cell therapies through a new distribution partnership. Kite is a Gilead Sciences company specializing in cell therapy for cancer treatment.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

Nanoscope Therapeutics selected InspiroGene to support distribution of its novel retinal therapy. The partnership enables Nanoscope to leverage McKesson's established distribution infrastructure.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

InspiroGene was selected as specialty pharmacy partner for Iovance's Amtagvi (lifileucel), the first cell therapy approved for solid tumors. InspiroGene provides end-to-end specialty pharmacy support for the product.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-01
Description

McKesson was selected to support specialty pharmacy and patient hub services for Precigen's novel immunotherapy launch. InspiroGene provides the specialized CGT capabilities for this partnership.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-01
Description

InspiroGene by McKesson partnered with Vertex to expand distribution options for CASGEVY (exagamglogene autotemcel), a gene therapy for sickle cell disease. This partnership extends patient access to Vertex's groundbreaking gene therapy.

6Biologics by McKesson
Strategic tierCoreTypeStrategic or Co-development Partner
Description

InspiroCare patient hub leverages the expertise of Biologics by McKesson to enhance both biopharma and patient experience throughout the CGT journey. Biologics provides the specialty pharmacy foundation and expertise for the integrated InspiroCare solution.

inspirogene.com
Strategic tierMinorTypeOthers
Description

Lumanity is listed as a partner on the InspiroGene About page. Lumanity is a healthcare communications and patient engagement company.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty pharmaceutical logistics and distribution provider (part of Cencora) with deep cold-chain capabilities serving cell and gene therapy manufacturers — a direct competitor to InspiroGene's 3PL and specialty distribution services.

TypeDirect peer
Description

Specialty pharma services provider across sterile manufacturing, packaging, and global supply chain, with growing CGT capabilities — comparable to InspiroGene's specialty distribution and specialty pharmacy services for advanced therapies.

TypeDirect peer
Description

Specialty logistics provider focused on temperature-controlled supply chain for cell and gene therapies, including cryogenic shipping and biostorage — directly comparable to InspiroGene's 3PL and cryo-storage capabilities for CGT manufacturers.

4Vineti
TypeEmerging player
Description

Cloud-based CGT supply chain orchestration platform helping manufacturers, treatment centers, and patients manage cell therapy workflows — an emerging competitor with partial overlap on the digital/ordering layer to InspiroGene's InspiroLink platform.

TypeDirect peer
Description

Global life sciences logistics provider offering temperature-controlled transportation, clinical trial logistics, and direct-to-patient services — competes with InspiroGene's 3PL and cold-chain distribution for cell and gene therapies.

TypeBroad incumbent
Description

Top-tier US pharmaceutical distributor with deep specialty distribution and patient services businesses (incl. World Courier, PharmaLex) — a broad incumbent that competes with McKesson and InspiroGene across CGT commercialization.

TypeBroad incumbent
Description

Major US pharmaceutical distributor and specialty services provider with nuclear pharmacy and at-home specialty distribution capabilities — a broad incumbent competing with McKesson/InspiroGene in the broader specialty distribution market including CGT-adjacent products.

TypeBroad incumbent
Description

Large-scale CDMO and specialty pharma services provider with biologics development, manufacturing, and integrated clinical/commercial supply services — a broader incumbent with overlapping capabilities in CGT commercialization support.

TypeBroad incumbent
Description

Biopharma commercialization services provider with patient access, hub, and specialty pharmacy offerings — a broad incumbent that overlaps with InspiroCare's patient hub services for CGT manufacturers.

TypeEmerging player
Description

Specialty biologic courier and clinical trial logistics provider with strong cold-chain and direct-to-patient capabilities — comparable to InspiroGene's transportation and cryo-logistics services for CGT products.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

InspiroGene

Cell and Gene Therapy Commercialization Servicesinspirogene.com

InspiroGene is McKesson's dedicated cell and gene therapy commercialization business unit, providing integrated 3PL, specialty distribution, specialty pharmacy, patient hub services, and the InspiroLink ordering platform to biopharma manufacturers across 95% of US CGT sites of care.

What InspiroGene does

InspiroGene is a wholly-owned business unit of McKesson Corporation (NYSE: MCK) that provides end-to-end commercialization services for cell and gene therapy (CGT) manufacturers. The platform integrates five service lines: Third-Party Logistics (3PL) with 12,000 sq ft of dedicated cryo/ultra-frozen storage within a 1 million sq ft Louisville, KY distribution center; Specialty Distribution with extensive treatment center coverage; Specialty Pharmacy with 50-state licensure and two redundant dispensing sites; the InspiroCare Patient Hub offering clinical case management, reimbursement support, and 24/7 care team access; and InspiroLink, a purpose-built ordering platform with API-level integrations across the CGT technology ecosystem. A distinguishing capability, Biologics-in-a-Box, co-locates specialty pharmacy dispensing within the 3PL environment to minimize manufacturer-to-treatment-center transit time. The unit covers 95% of active CGT sites of care and is staffed by teams with an average of 10+ years of CGT commercialization experience.

The company operates as a B2B enterprise service provider, targeting biopharma companies commercializing cell and gene therapies through a dedicated field sales motion and configurable engagement models (high-touch, configurable, or purpose-built). Revenue is generated through managed services fees, distribution and transaction fees, pharmacy dispensing fees, and biopharma-sponsored hub service agreements. Pricing is not publicly disclosed and is tailored per manufacturer. InspiroGene's named enterprise customers include Kite Pharma (CAR T-cell distribution), Vertex Pharmaceuticals (CASGEVY gene therapy distribution), Iovance Biotherapeutics (Amtagvi specialty pharmacy, the first FDA-approved cell therapy for solid tumors), Nanoscope Therapeutics (retinal gene therapy distribution), and Precigen (specialty pharmacy and patient hub for immunotherapy launch).

Strategically, InspiroGene leverages McKesson's Fortune 10 infrastructure, 300+ manufacturer relationships, $300B+ in annual WAC sales across full-line wholesale and specialty distribution, and a 450+ person multi-site logistics operation. The unit was launched in 2024 and has rapidly accumulated enterprise partnerships through 2026, supported by thought leadership content (annual CGT Report), industry event participation, and a marketing motion centered on positioning as an 'ally' to biopharma companies navigating CGT commercialization complexity. The platform's strategic intent is to capture share of the rapidly expanding CGT pipeline (235+ therapies analyzed in 2025) by offering integrated, CGT-specialized commercialization infrastructure that bridges the gap between therapy innovation and patient access.

InspiroGene firmographics

Firmographics
Name
InspiroGene
Legal name
InspiroGene (Trademark of McKesson Corporation)
Website
https://inspirogene.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
1–10 employees
Short description
InspiroGene is McKesson's dedicated cell and gene therapy commercialization business unit, providing integrated 3PL, specialty distribution, specialty pharmacy, patient hub services, and the InspiroLink ordering platform to biopharma manufacturers across 95% of US CGT sites of care.
Ownership category
akta.pro rank

InspiroGene industry classification

Industry
Product category
Cell and Gene Therapy Commercialization Services
NAICS
Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAIAJAH
Biologics & Biosimilars Distributors
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Cell therapy logistics
  • Gene therapy distribution
  • Specialty pharmacy services
  • Patient hub services
  • Biologics distribution

Where InspiroGene is headquartered

Location

Headquarters

HQ city
Irving
HQ country
United States
HQ region
North America

Offices2 records

Markets served

InspiroGene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Third-Party Logistics (3PL) Services: Comprehensive 3PL services for CGT manufacturers including warehousing, distribution, transportation, customer service, and full order-to-cash services. Supports title and non-title distribution models with over $3B in annual revenue. Revenue generated through service fees for logistics, storage, kitting, and relabeling solutions.
  2. Specialty Distribution Services: Specialty distribution services with extensive treatment center coverage and optimized cash cycle management for CGT therapies. Revenue generated through distribution fees, logistics services, and financial management services.
  3. Specialty Pharmacy Services: End-to-end specialty pharmacy support for manufacturers, HCPs, payers, QTCs, and patients. Includes dispensing, reimbursement support, and patient management services. Revenue generated through pharmacy dispensing fees and service agreements.
  4. InspiroCare Patient Hub Services: Purpose-built patient HUB services providing clinical case management, reimbursement, education, and financial assistance coordination. Revenue generated through biopharma-sponsored hub service agreements.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

InspiroGene product offering

Product offering

Core offering

InspiroGene provides integrated commercialization services for cell and gene therapy (CGT) manufacturers, spanning third-party logistics (3PL) with cryo/cold-chain storage, specialty distribution, specialty pharmacy dispensing, and patient hub services (InspiroCare), all unified by the InspiroLink ordering platform. The offering is purpose-built for CGT commercialization, covering 95% of active US CGT sites of care and supporting biopharma manufacturers with end-to-end order-to-cash, reimbursement, and patient access workflows.

Product overview

InspiroGene by McKesson is a cell and gene therapy (CGT) commercialization platform offering an integrated suite of services. The core portfolio consists of five interconnected service lines: Third-Party Logistics (3PL) for storage, warehousing, and distribution; Specialty Distribution for treatment center coverage and logistics; Specialty Pharmacy for dispensing and patient management; InspiroCare Patient Hub for patient support and coordination; and InspiroLink as the central ordering and tracking platform. The platform is purpose-built for CGT with specialized features including cryo/ultra-frozen storage solutions, Biologics-in-a-Box for streamlined product transit, and a Drive-By pharmacy model. Supported by McKesson's established infrastructure and 10+ years of CGT expertise, the solution covers 95% of active CGT sites of care across the US.

Differentiator

Problem solved

Functional benefit

Brands

  • InspiroCare: Patient HUB services for cell and gene therapy, providing personalized case management, financial assistance coordination, travel and logistics support, and educational resources for patients and caregivers.
  • InspiroLink

Products and services

  • Third-Party Logistics (3PL) Comprehensive third-party logistics services tailored for cell and gene therapy manufacturers, including cryo/ultra-frozen storage solutions, ordering systems, cash management, logistics, and data analytics; licensed across all 50 states and territories.
  • Specialty Distribution Specialty distribution network with extensive treatment center coverage and optimized cash cycle management for cell and gene therapies, offering high-touch logistics and advanced data analytics.
  • Specialty Pharmacy Purpose-built specialty pharmacy services dedicated to CGT for seamless site readiness, streamlined patient access and reimbursement processes, and high-touch dispensing with ongoing patient management; 50-state licensure with 2 redundant dispensing sites.
  • InspiroCare Patient Hub Purpose-built patient hub services providing personalized, compassionate support to help patients, caregivers, and providers navigate the CGT journey, including clinical case management, reimbursement support, patient education, financial assistance coordination, and 24/7 access to the care team.
  • InspiroLink Ordering Platform A purpose-built ordering application for healthcare providers ordering cell, gene, and advanced therapy treatments, supporting customized order workflows, scheduling, real-time product tracking, and API integrations across the Cell and Gene technology ecosystem.
  • Treatment Center Experience Purpose-built support for CGT commercialization at treatment centers, including site readiness, efficient site activation, and reliable patient access, leveraging McKesson's national network of treatment centers.

Quantifiable outcome

  • 95% of active CGT sites of care covered
  • +6 more outcomes

Companies that use InspiroGene

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles2 records

InspiroGene technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

InspiroGene partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Kite PharmacoreChannel Partner/ Reseller/ Distributor · 1 June 2026InspiroGene by McKesson expanded U.S. patient access to Kite's CAR T-cell therapies through a new distribution partnership. Kite is a Gilead Sciences company specializing in cell therapy for cancer treatment.
  • Nanoscope TherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 May 2026Nanoscope Therapeutics selected InspiroGene to support distribution of its novel retinal therapy. The partnership enables Nanoscope to leverage McKesson's established distribution infrastructure.
  • Iovance BiotherapeuticscoreChannel Partner/ Reseller/ Distributor · 1 September 2025InspiroGene was selected as specialty pharmacy partner for Iovance's Amtagvi (lifileucel), the first cell therapy approved for solid tumors. InspiroGene provides end-to-end specialty pharmacy support for the product.
  • PrecigencoreChannel Partner/ Reseller/ Distributor · 1 September 2025McKesson was selected to support specialty pharmacy and patient hub services for Precigen's novel immunotherapy launch. InspiroGene provides the specialized CGT capabilities for this partnership.
  • Vertex PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 November 2024InspiroGene by McKesson partnered with Vertex to expand distribution options for CASGEVY (exagamglogene autotemcel), a gene therapy for sickle cell disease. This partnership extends patient access to Vertex's groundbreaking gene therapy.
  • Biologics by McKessoncoreStrategic or Co-development PartnerInspiroCare patient hub leverages the expertise of Biologics by McKesson to enhance both biopharma and patient experience throughout the CGT journey. Biologics provides the specialty pharmacy foundation and expertise for the integrated InspiroCare solution.
  • LumanityminorOthersLumanity is listed as a partner on the InspiroGene About page. Lumanity is a healthcare communications and patient engagement company.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

InspiroGene competitors and assessment

Company assessment

Direct peers

  • World Courier (Cencora): Specialty pharmaceutical logistics and distribution provider (part of Cencora) with deep cold-chain capabilities serving cell and gene therapy manufacturers — a direct competitor to InspiroGene's 3PL and specialty distribution services.
  • PCI Pharma Services: Specialty pharma services provider across sterile manufacturing, packaging, and global supply chain, with growing CGT capabilities — comparable to InspiroGene's specialty distribution and specialty pharmacy services for advanced therapies.
  • Cryoport: Specialty logistics provider focused on temperature-controlled supply chain for cell and gene therapies, including cryogenic shipping and biostorage — directly comparable to InspiroGene's 3PL and cryo-storage capabilities for CGT manufacturers.
  • Marken (UPS Healthcare): Global life sciences logistics provider offering temperature-controlled transportation, clinical trial logistics, and direct-to-patient services — competes with InspiroGene's 3PL and cold-chain distribution for cell and gene therapies.

Emerging players

  • Vineti: Cloud-based CGT supply chain orchestration platform helping manufacturers, treatment centers, and patients manage cell therapy workflows — an emerging competitor with partial overlap on the digital/ordering layer to InspiroGene's InspiroLink platform.
  • Yourway: Specialty biologic courier and clinical trial logistics provider with strong cold-chain and direct-to-patient capabilities — comparable to InspiroGene's transportation and cryo-logistics services for CGT products.

Broad incumbents

  • Cencora (formerly AmerisourceBergen): Top-tier US pharmaceutical distributor with deep specialty distribution and patient services businesses (incl. World Courier, PharmaLex) — a broad incumbent that competes with McKesson and InspiroGene across CGT commercialization.
  • Cardinal Health: Major US pharmaceutical distributor and specialty services provider with nuclear pharmacy and at-home specialty distribution capabilities — a broad incumbent competing with McKesson/InspiroGene in the broader specialty distribution market including CGT-adjacent products.
  • Catalent: Large-scale CDMO and specialty pharma services provider with biologics development, manufacturing, and integrated clinical/commercial supply services — a broader incumbent with overlapping capabilities in CGT commercialization support.
  • Syneos Health: Biopharma commercialization services provider with patient access, hub, and specialty pharmacy offerings — a broad incumbent that overlaps with InspiroCare's patient hub services for CGT manufacturers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

InspiroGene social profiles

Digital presence

InspiroGene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

InspiroGene leadership team

Management profile

Number of profiles

Profiles8 records

InspiroGene funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

InspiroGene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about InspiroGene

What does InspiroGene do?

InspiroGene provides integrated commercialization services for cell and gene therapy (CGT) manufacturers, spanning third-party logistics (3PL) with cryo/cold-chain storage, specialty distribution, specialty pharmacy dispensing, and patient hub services (InspiroCare), all unified by the InspiroLink ordering platform. The offering is purpose-built for CGT commercialization, covering 95% of active US CGT sites of care and supporting biopharma manufacturers with end-to-end order-to-cash, reimbursement, and patient access workflows.

Is InspiroGene a public or private company?

InspiroGene is a private company. It is classified as corporate owned and is currently operating.

When was InspiroGene founded?

InspiroGene was founded in 2022. It employs 1 to 10 people.

Where is InspiroGene based?

InspiroGene is headquartered in Irving, United States, in the North America region.

How does InspiroGene make money?

Four revenue lines are on record. Third-Party Logistics (3PL) Services are the primary driver. The others are specialty Distribution Services, specialty Pharmacy Services and inspiroCare Patient Hub Services.

Who are InspiroGene's main competitors?

Direct peers on record are World Courier (Cencora), PCI Pharma Services, Cryoport and Marken (UPS Healthcare). Emerging players are Vineti and Yourway. Broad incumbents are Cencora (formerly AmerisourceBergen), Cardinal Health, Catalent and Syneos Health.

Does InspiroGene have an API?

No public API is recorded for InspiroGene.

What industry is InspiroGene in?

InspiroGene's product category is Cell and Gene Therapy Commercialization Services. Its primary akta.pro industry code is HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 524292 and its SIC code is 5047.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal TherapyNanoscope Therapeutics selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product MOGENRY, subject to regulatory approval. The collaboration covers specialty pharmacy, distribution, and patient hub services to support the first optogenetic gene therapy launch. Nanoscope plans a Phase 3 registrational trial in 2026.PR NewswireNanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal TherapyNanoscope Therapeutics selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product MOGENRY, subject to regulatory approval. The collaboration covers specialty pharmacy, distribution, and patient hub services to support the first optogenetic gene therapy launch in the U.S. The company has initiated a rolling BLA submission to the FDA.McKessonSafeguarding Cell and Gene Therapies with InspiroGene's Cold Chain FacilityInspiroGene has opened a specialized cold chain facility in Clermont, Kentucky, designed to meet the stringent storage and distribution needs of cell and gene therapies (CGTs). The facility, which spans 12,000 square feet within a larger distribution center, features advanced technology for cryogenic storage and has an integrated specialty pharmacy to streamline therapy dispensing. This development supports the growing demand for CGTs and enhances the reliability of therapy distribution across the United States.McKessonBreaking Barriers to Cell and Gene Therapy AccessCell and gene therapies (CGTs) are advancing medical treatment for serious diseases, as highlighted in the 2025 Cell and Gene Therapy Report by InspiroGene, a part of McKesson. The report outlines significant barriers to widespread access, such as costs and geographical distribution, and emphasizes the need for collaboration among stakeholders to improve patient access to these therapies. Experts suggest that overcoming these challenges is essential for realizing the full potential and expanding the reach of CGTs.McKessonCell and Gene Therapies on the Rise: New Report Reveals Growing Adoption and Persistent ChallengesInspiroGene by McKesson published its second annual 2025 Cell and Gene Therapy Report, revealing that while oncologist familiarity with cell and gene therapies (CGTs) is growing (60% very familiar, up from 55% in 2024) and the average number of patients treated annually has risen from 17 to 25, significant barriers remain with 66% of patients viewing CGTs as "too experimental" and payers citing cost and durability as key reimbursement challenges. The report also found that the number of qualified CGT treatment centers in the U.S. remained flat from 2024 to 2025, while 178 oncology-focused drug candidates entered the late-stage pipeline in the past year alone.Business Wire BlogInspiroGene by McKesson Unveils First-of-its-Kind Report on State of the Cell and Gene Therapy Landscape, Revealing Unparalleled Optimism Amidst Complex ChallengesInspiroGene by McKesson released its 2024 Cell and Gene Therapy Report, based on a survey of 124 U.S. oncologists. The report finds 99% of oncologists see CGTs as important, but 64% say they are not easily accessible, and 47% say patients are rarely aware of availability.McKessonMcKesson Launches InspiroGeneMcKesson Corporation launched InspiroGene, a dedicated business unit focused on supporting the commercialization of cell and gene therapies. This new entity provides specialized logistics, distribution, pharmacy solutions, and technology platforms to help manufacturers and providers navigate the complex CGT landscape.